| Target Validation Information | |||||
|---|---|---|---|---|---|
| TTD ID | T22032 | ||||
| Target Name | Parathyroid hormone receptor (PTH2R) | ||||
| Type of Target |
Clinical trial |
||||
| Drug Potency against Target | Drug Info | IC50 = 700 nM | [1] | ||
| Action against Disease Model | Ostabolin-C | Drug Info | H uMan bone marrow stromal cells (hMSCs) have the potential to differentiate into osteoblasts. Ostabolin-C (10 nM) stimulated osteoblast differentiation with hMSCs | [2] | |
| References | |||||
| REF 1 | Novel parathyroid hormone (PTH) antagonists that bind to the juxtamembrane portion of the PTH/PTH-related protein receptor. J Biol Chem. 2005 Jan 21;280(3):1797-807. | ||||
| REF 2 | Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro. Cancer Res. 1994 Feb 15;54(4):1035-41. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.